Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00799773 · ClinicalTrials.gov registry record · Phase 3
Evaluating the Effectiveness of Adding Rituximab to Standard Treatment for Thrombotic Thrombocytopenic Purpura (TTP)
A Phase 3 study, sponsored by Carelon Research.
- Terminated
- Registry status
- Phase 3
- Development phase
- 3
- Enrollment target
NCT00799773 is a Phase 3 study that was terminated before completion, run by Carelon Research. The registered enrollment target is 3 participants.
The verdict
NCT00799773, a Phase 3 study, was terminated before completion, sponsored by Carelon Research.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 3 participants
- Enrollment target
Study Summary
Thrombotic thrombocytopenic purpura (TTP) is a rare disorder that causes blood clots to form in blood vessels. The main treatment for TTP is plasma exchange, in which affected patients receive transfusions of plasma, the liquid part of blood, from healthy donors. This study will examine the effectiveness of an antibody, rituximab, in combination with plasma exchange, at improving the immune response in people with TTP and decreasing the recurrence of TTP.
Interventions
- DRUG Rituximab
- PROCEDURE Plasma exchange
- DRUG Corticosteroids
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2009-04 |
| Est. Completion | 2010-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00799773
The ClinicalTrials.gov registry entry for NCT00799773 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Carelon Research, which has 50 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Rituximab is the first listed.
NCT00799773 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00799773 about?
NCT00799773 is a clinical study titled "Evaluating the Effectiveness of Adding Rituximab to Standard Treatment for Thrombotic Thrombocytopenic Purpura (TTP)". Thrombotic thrombocytopenic purpura (TTP) is a rare disorder that causes blood clots to form in blood vessels. The main treatment for TTP is plasma exchange, in which affected patients receive transfusions of plasma, the liquid part of blood, from healthy donors. This study will examine the effectiv...
What is the current status of trial NCT00799773?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 3 participants. The study started on 2009-04. Estimated completion is 2010-02.
What interventions are being tested in trial NCT00799773?
The interventions under investigation include: Rituximab (DRUG), Plasma exchange (PROCEDURE), Corticosteroids (DRUG).
Who is sponsoring clinical trial NCT00799773?
This trial is sponsored by Carelon Research, which has 50 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.